Safety and Efficacy of Pembrolizumab Prior to Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia
Open Access
- 1 December 2021
- journal article
- research article
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 27 (12) , 1021.e1-1021.e5
Abstract
No abstract availableKeywords
Funding Information
- Amgen
- Merck Sharp & Dohme Ltd
- Novartis
- Bristol-Myers Squibb
- Jazz Pharmaceuticals
- Gilead Sciences
- AstraZeneca
- Astex Pharmaceuticals
- Celgene
- Genentech
- Daiichi-Sankyo
- AbbVie
- Dainippon Sumitomo Pharma
- Takeda Pharmaceuticals U.S.A.
- Merck
- GlaxoSmithKline
This publication has 15 references indexed in Scilit:
- Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphomaLeukemia, 2021
- Immune Checkpoint Inhibitors in AML-A New FrontierCurrent Cancer Drug Targets, 2020
- Expression patterns of immune checkpoints in acute myeloid leukemiaJournal of Hematology & Oncology, 2020
- Characterization of Immune Dysfunction and Identification of Prognostic Immune-Related Risk Factors in Acute Myeloid LeukemiaClinical Cancer Research, 2020
- Posttransplantation cyclophosphamide improves transplantation outcomes in patients with AML/MDS who are treated with checkpoint inhibitorsCancer, 2020
- Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 studyThe Lancet Haematology, 2019
- Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II StudyCancer Discovery, 2019
- Significant Risk of Graft-versus-Host Disease with Exposure to Checkpoint Inhibitors before and after Allogeneic TransplantationTransplantation and Cellular Therapy, 2019
- Immune checkpoint inhibitors as a bridge to allogeneic transplantation with posttransplant cyclophosphamideBlood Advances, 2018
- Clinical Development of PD-1 Blockade in Hematologic MalignanciesThe Cancer Journal, 2018